Last Tuesday (November 18th), we had the privilege of participating in person in the CADIFA 2025 Seminar at Anvisa headquarters. The event aimed to present updates related to CADIFA.

Our Dashboard just got an important update! In addition to information on manufacturers with CBPF, you can now also track CADIFA data – making it an even more complete tool to support strategic decisions in the Brazilian market.

The Technical Note 34/2024, shared by Anvisa earlier this year, provides important clarifications regarding CBPF certification for API manufacturers. Are you familiar with how this information might impact your processes?

IN 289/2024 outlines the criteria for the optimized analysis procedure, which relies on assessments by Equivalent Foreign Regulatory Authorities (AREE) for the registration and post-registration of medicines, biological products, vaccines, and Active Pharmaceutical Ingredient Dossier (CADIFA).

查看本周从 ANVISA 收到 CBPF (GMP) 的 API 制造公司。 该文件包括向生物、半合成和合成 API 制造商颁发的认证——数据来源：国家卫生监督局 – 官方公报。

We are thrilled to announce that the CBPF dashboard is now live! Designed to enhance the connection between API manufacturers and Brazilian pharmaceutical companies, this innovative tool will not only boost the visibility of API manufacturers in the Brazilian market but also streamline the sourcing process for drug manufacturers seeking reliable API suppliers.

Check the API manufacturing companies that received CBPF (GMP) from ANVISA this week.  The document includes certification issued to biological, semisynthetic, and synthetic API manufacturers—data source: National Health Surveillance Agency – Official Gazette.